Colorectal Cancer Screening Recommendations
Colorectal cancer screening should begin at age 45 for average-risk individuals and continue through age 75, with colonoscopy every 10 years or annual fecal immunochemical test (FIT) as preferred first-tier options. 1, 2
Starting Age for Screening
- The American Cancer Society, US Preventive Services Task Force (USPSTF), and National Comprehensive Cancer Network (NCCN) all recommend beginning colorectal cancer screening at age 45 for average-risk individuals 1, 2
- The recommendation to begin screening at age 45 is based on:
- For individuals with a family history of CRC in a first-degree relative, screening should begin at age 40 or 10 years before the age of diagnosis of the youngest affected relative, whichever comes first 1, 3
- African American individuals should begin screening at age 45 due to higher incidence rates 2
Recommended Screening Tests
- First-tier options (strongly recommended):
- Second-tier options (for those who decline first-tier tests):
When to Stop Screening
- Individuals who are up to date with screening and have negative prior screening tests (particularly high-quality colonoscopy) should consider stopping screening at age 75 years 1, 4
- For persons aged 76-85 years without prior screening, decisions should be individualized based on:
- Screening should not be offered to individuals age 86 and older as the risks outweigh the benefits 5, 4
- Individuals with severe comorbidities should stop screening at age 66 regardless of prior screening history 2, 4
Special Considerations
- Persons with Lynch Syndrome should begin colonoscopy 10 years before the age at diagnosis of the youngest affected relative 1
- Never delay evaluation of symptomatic individuals regardless of age, especially those with bleeding symptoms 1
- The benefits of continued screening decrease with age while potential harms increase 4, 6
- Having health insurance significantly increases the likelihood of receiving appropriate screening 7
Common Pitfalls to Avoid
- Continuing screening beyond age 85 when evidence shows harms outweigh benefits 1, 4
- Stopping screening too early in healthy individuals with no prior screening history 2, 4
- Not considering race-specific recommendations, particularly for African American individuals 2
- Not screening first-degree relatives of CRC patients beginning at age 40, as screening rates in this high-risk group aged 40-49 lag significantly behind those aged 50+ 7
- Not recognizing that any screening is better than none - patient preferences and local resource availability should be considered to increase screening uptake 8